LFB USA is led by a team of business experts and scientists with a successful track record of developing and commercializing important and highly innovative healthcare technologies and life-changing therapeutics.
Jose Antonio Moreno Toscano
Chief Executive Officer
Jose Antonio Moreno Toscano is the current LFB USA Chief Executive Officer, bringing significant global leadership experience to the Company.
Prior to joining LFB, Jose served as President of Safe Harbor Compliance and Clinical Services, where he is also a Board member. He also led the US & Canadian subsidiaries of ALK, a publicly held Danish company that is the world leader in allergy and immunotherapy care. He held full P&L and operational responsibility for ALK’s Americas region, successfully growing the top and bottom line via both organic growth and accretive acquisitions. Prior to his role at ALK, Jose served as Chief Financial Officer for Applus A/S in Copenhagen. He began his career in Corporate Development and Investor Relations, where he led M&A activities at Chr. Hansen Holding, a world leader in biosciences focused on developing and commercializing ingredients for the food, agricultural and pharmaceutical industries.
Jose brings a global perspective to our business, having lived and worked in several European countries as well as the US. Jose earned his Master’s Degree in Law from the Universidad de Murcia in Spain and his MBA in International Finance and Strategy from the ENPC School of International Management in Paris.
William Gavin, D.V.M.
Chief Operating Officer
Dr. Gavin has held various positions of increasing responsibility within the Company since 1994, including President. Prior to becoming Chief Operating Officer, he was Senior Vice President of Operations and responsible for the company’s production programs and transgenic animal development as well as many of the Operational components within the company including Farm Operations, Dairy Operations, Veterinary Services, Facilities, Occupational Health and Safety, Security and Logistics. Dr. Gavin has been with the company for 20+ years and working in this field and with this platform of production for 25+ years. Dr. Gavin is well published, presents internationally, and is also named on numerous international patents. He was instrumental in the development of the production facility in central Massachusetts and responsible for overseeing the site through to the first ever Regulatory approval and licensure for the rPRO Technology™ by the EMA, FDA-CBER and FDA-CVM. He holds a Bachelors degree in Animal Science with honors from the University of Massachusetts and a Doctorate in Veterinary Medicine with honors from Tufts University.